Quick Facts

• Targeted Conditions: Used for the management of certain bacterial infections.
• Therapeutic Domains: Approved for use in lower respiratory tract, upper respiratory tract, skin, and urinary tract infections.
• Mechanism of Action: Works to discourage the growth of susceptible bacteria.

Keflor is a medication for managing a variety of infections caused by specific strains of susceptible bacteria. Its use is focused on treating acute bacterial infections in different bodily systems.

Key areas where Keflor is indicated include lower respiratory tract infections, which may involve pneumonia or acute exacerbations of chronic bronchitis. It also addresses infections of the upper respiratory tract, such as otitis media (middle ear infection), pharyngitis, and tonsillitis.

Furthermore, the medication is an option for certain infections affecting the skin and associated structures, as well as urinary tract infections, including both cystitis and pyelonephritis. All treatment decisions should be based on identifying the susceptible causative organism to ensure appropriate care.

Regulatory References

1. FDA drug label guidance for Cefaclor

Eligibility Map: Who can and cannot use Keflor — official regulatory information

Eligibility scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and the pediatric population aged one month and older are approved for use. Geriatric patients may receive the adult dose, subject to monitoring.
Populations for whom use is not recommended (if applicable)	Safety and efficacy have not been established for infants less than one month of age; use is not recommended in this group.
Populations for whom use is contraindicated	Use is prohibited for patients with known hypersensitivity to Cefaclor or any antibiotic in the cephalosporin class. A past severe allergic reaction to penicillin is also an exclusion due to cross-allergenicity.
Age-related eligibility rules	The medicine is not established for infants under one month. Older adults require caution due to increased risk of neurotoxicity.
Condition-specific eligibility rules	Caution is advised for patients with markedly impaired renal function and a history of gastrointestinal disease, particularly colitis.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy use is conditional and should occur only if clearly needed. Use during lactation is generally considered acceptable by regulators.
Eligibility-related restrictions	Patients with Penicillin sensitivity require cautious administration due to the potential for cross-allergenicity.

---

Eligibility classifications (high-level)

Classification	Regulatory Basis
Eligibility severity classification (as defined in official documents)	Contraindicated (for allergy), Not Established (for infants < 1 month), and Caution (for renal/GI impairment).
Regulatory basis (EMA / FDA / etc.)	FDA Prescribing Information, EMA-related SmPCs, and other national health authorities.
Eligibility-context constraints (as defined in official documents)	Constraints are primarily based on immunological status, age, and pre-existing organ or gastrointestinal conditions.

---

Resulting eligibility structure

Official eligibility statements:

• The definitive non-eligible group is determined by a cephalosporin allergy.
• Use is explicitly not established in infants under one month of age.
• Use is conditional on the need for caution in patients with impaired renal function or a history of colitis.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define who can and cannot use the medicine by specifying non-negotiable contraindications (allergy) and establishing clear cautions for use in patient groups with organ impairment or age-related risks. The resulting profile dictates a restricted use environment to manage known immunological and systemic concerns.

Interactions with other medicines and products

Regulatory documents outline specific interactions that affect the exposure and systemic effects of Keflor (Cefaclor).

Category	Official Regulatory Statement
Specific Interacting Medicines	Probenecid, oral anticoagulants (e.g., Warfarin, Acenocoumarol), estrogen-containing oral contraceptives, and antacids containing aluminum or magnesium hydroxide.
Mechanistic Basis	Inhibition of Cefaclor renal excretion (by Probenecid), effects on prothrombin time (by oral anticoagulants), and diminution of Cefaclor absorption (by antacids).
Timing-Based Rules	Antacids containing aluminum or magnesium hydroxide must be administered with separation; the official regulatory mandate specifies that absorption is diminished if these antacids are taken within one hour of Cefaclor administration.
Food Interaction	The official label states that food may reduce the Cmax and AUC (measures of exposure) of the Cefaclor extended-release tablet formulation.

Official Interaction Statements:

• Probenecid is formally documented to inhibit the renal excretion of Cefaclor, which results in increased serum concentrations and a prolonged half-life.
• Co-administration with oral anticoagulants has been officially associated with an increase in prothrombin time, with reported occurrences of clinical bleeding.
• Cefaclor may formally decrease the efficacy of estrogen-containing oral contraceptives.

Connection to the overall interaction profile:

Regulatory documents define the interaction structure of Cefaclor by detailing patterns of pharmacokinetic interference with renal transporters and absorption, along with a pharmacodynamic effect that modifies the patient's coagulation status. This structure establishes specific constraints on co-administration to maintain predictable drug exposure and mitigate the potential for officially recognized systemic effects.

The action of Cefaclor is defined by a bactericidal mechanism, characterized by the physical disruption of the structural integrity of the bacterial cell wall.

Irreversible Inactivation of Cell Wall Construction Enzymes

Cefaclor is a beta-Lactam antibiotic that works by binding covalently and irreversibly inhibiting a group of bacterial enzymes called Penicillin-Binding Proteins (PBPs). These PBPs are critical for catalyzing the final step in the synthesis of the bacterial cell wall—the peptidoglycan cross-linking. By acting as a false substrate, Cefaclor permanently blocks the transpeptidase activity, which halts the formation of the cell's rigid structural scaffold. This failure in cell wall assembly is the molecular event that precipitates the ensuing bacterial cell death.

Cascading Failure and Loss of Osmotic Control

The cessation of peptidoglycan cross-linking leads to a structural defect in the bacterial cell wall. This defect, combined with the activation of the bacteria's own latent autolytic enzymes, results in a loss of the cell's ability to withstand internal pressure. The resulting sequence of osmotic lysis and cell rupture leads to bacterial cell death, defining the drug's bactericidal activity profile.

Biological Limitations: The Role of Bacterial Resistance

The mechanism is constrained by bacterial factors, primarily the production of beta-Lactamase enzymes. These enzymes chemically inactivate Cefaclor by hydrolyzing its beta-Lactam ring before it can reach the PBPs. Resistance can also arise from alterations in the PBP structure itself, which lowers the enzyme’s affinity for Cefaclor.

How Keflor is Used: Official Administration Guidelines

Keflor (Cefaclor) is an antibiotic approved for oral administration and is available in three primary formulations: capsules, powder for oral suspension, and extended-release tablets. Dosing and preparation follow the specifications outlined in the prescribing information to ensure correct use.

---

Standard Dosing and Frequency

The dosage regimen varies based on the severity of the infection and the specific formulation used. Treatment is typically continued for a minimum of 48 to 72 hours after symptoms subside.

Formulation	Typical Adult Dosing Regimen	Maximum Recommended Dose (Adult)
Capsules / Suspension	250 mg to 500 mg every 8 hours (three times daily)	4 g per day
Extended-Release Tablets	375 mg to 750 mg every 12 hours (twice daily)	Not specified in all labels

For infections caused by Group A beta-haemolytic streptococci, therapy must be maintained for at least 10 days.

---

Specific Administration and Population Rules

• With or Without Food: The medicine may be taken with or without food as the total absorption is not affected, although food may delay the time to peak concentration.
• Extended-Release Form: Extended-release tablets must be swallowed whole and must not be cut, crushed, or chewed.
• Oral Suspension: The powder requires reconstitution with water and must be refrigerated after mixing. Any unused portion should be discarded after 14 days.
• Pediatric Use: For children over one month of age, the dosage is typically weight-based, ranging from 20 mg/kg/day to 40 mg/kg/day in divided doses.
• Renal Impairment: Dose adjustment is generally not required in patients with moderate to severe renal impairment, though it should be administered with caution.

Research Evidence / Overview of Studies for Keflor

Evidence for Use in Respiratory Tract Infections (Lower and Upper)

Research exploring Cefaclor for respiratory infections consists primarily of Randomized Controlled Trials (RCTs) and controlled comparative studies. These studies were used in research exploring whether symptoms changed during the study period when individuals had conditions associated with acute or disruptive episodes, such as pneumonia, acute bronchitis, acute otitis media (AOM), and pharyngitis. The research examined groups of both adults and children.

In studies for AOM, researchers studied short-term treatment courses. They measured outcomes related to physical discomfort and monitored changes in the visible signs of infection. Trials reported patterns observed in the eradication rates of the bacteria thought to cause AOM. For Pharyngitis and Tonsillitis, Cefaclor was evaluated in comparative studies that monitored outcomes related to systemic or functional imbalance by measuring the elimination of specific pathogens. Studies show patterns related to immediate eradication, but the consistency of these patterns over extended periods remains an area where evidence is limited.

Evidence for Use in Uncomplicated Urinary Tract and Skin Infections

Research explored the use of Cefaclor for conditions marked by functional limitations like uncomplicated urinary tract infections (UTIs) and certain skin and skin structure infections. The evidence largely derives from older, short-term clinical trials. For Uncomplicated UTIs, research examined temporary physiological imbalance by measuring pathogen elimination and monitoring outcomes related to physical discomfort. Data show patterns related to microbiologic clearance were observed in some studies, but research describes limitations regarding the applicability of these older findings in the context of current resistance patterns.

What is Still Uncertain in the Research Landscape

Most research on Cefaclor involves short-term clinical trials with limited follow-up durations. Long-term effects and the durability of the reported findings are not fully established for many indications. Furthermore, comparative evidence is lacking regarding Cefaclor versus many of the newest antibiotic classes. Data for certain specific groups, such as older adults with multiple chronic conditions, remain insufficient. The research conducted so far contributes to the broader evidence landscape, but highlights where certainty remains low.

Key Studies & References

1. NIH MedlinePlus: Cefaclor - Description, Forms, and Administration
2. FDA Drug Label Guidance for Cefaclor: Indications and Usage (Set ID: 9f919252-7a87-4386-a64c-5d8213f7e881)

Common questions about Keflor (FAQ)

Q: What is the main purpose of Keflor (cefaclor) and what types of infections does it treat?

Official product information states that Keflor is indicated for treating infections caused by susceptible bacteria. This includes infections of the lower and upper respiratory tracts, such as otitis media, pharyngitis, and pneumonia, as well as infections of the skin and urinary tract.

Q: What is the difference between Keflor and other cephalosporin antibiotics like Keflex (cephalexin)?

Keflor (Cefaclor) is classified as a second-generation cephalosporin antibiotic. This classification, according to official regulatory data, signifies that it has a spectrum of activity that targets a broader range of Gram-negative bacteria, such as Haemophilus influenzae, compared to first-generation cephalosporin agents.

Q: What are the signs of a severe allergic reaction to Keflor that require immediate medical attention?

Regulatory documents describe severe allergic reactions as potentially including signs like hives, rash, or intense itching, alongside swelling of the face, lips, tongue, or throat. These manifestations are described in regulatory documents as signs of a severe reaction.

Q: How does Keflor compare to penicillin for treating streptococcal infections?

Official information describes penicillin as the usual drug of choice for treating and preventing streptococcal infections. While studies indicate Keflor can effectively eliminate streptococci from the nasopharynx, evidence establishing its efficacy for preventing complications like rheumatic fever is considered limited.

Q: What is the risk of developing Clostridium difficile-associated diarrhea (CDAD) with Keflor?

Clostridium difficile-associated diarrhea (CDAD), including severe pseudomembranous colitis, is a recognized risk reported with nearly all antibacterial agents, including Keflor. This serious condition is associated with antibiotic use, and symptoms may appear during or even after treatment has ended.

Q: Can Keflor affect the results of any common lab tests, such as urine sugar tests?

Keflor is documented to potentially interfere with specific types of laboratory tests. According to official labeling, it may cause a false-positive reaction when testing for glucose in the urine using non-enzyme-based methods like Benedict's solution, Fehling's solution, or Clinitest tablets.

Q: What are the official warnings regarding neurotoxicity or seizures associated with Keflor use?

The official label lists seizures as a rare adverse reaction under nervous system disorders. The risk of seizures has been implicated across the cephalosporin class, particularly in patients with impaired kidney function if the dosage is not properly reduced.

Q: What does a 'cephalosporin' antibiotic mean in simple terms?

A cephalosporin is a type of antibiotic belonging to the beta-lactam class. These medicines function by disrupting the formation of the protective wall that surrounds bacterial cells, a mechanism that ultimately leads to the death of the bacteria.

Q: How should the liquid suspension form of Keflor be measured and prepared?

Official guidance states that the powder for suspension requires reconstitution with water and must be shaken well before each use. Regulatory guidance states that doses must be measured accurately using a proper oral dosing tool, such as an oral syringe, dropper, or measuring cup/spoon.

Q: If a person feels stomach upset while taking Keflor, does taking it with food help?

Regulatory patient leaflets suggest that if stomach upsets, such as nausea or vomiting, are experienced, taking Keflor with food may help to ease these symptoms.

Q: What happens in the body to cause a delayed allergic reaction (serum sickness-like reaction) to Keflor?

Serum sickness-like reactions are classified as delayed hypersensitivity reactions. These reactions are associated with findings like skin rashes and joint pain (arthralgia), and they are described as occurring during a second or subsequent course of therapy.

Q: Are there any documented cases of kidney damage linked to Keflor (cefaclor) use?

Regulatory documents list renal dysfunction and transient interstitial nephritis (inflammation of the kidney) as possible adverse reactions reported within the cephalosporin class of antibiotics. Caution for use in patients with existing impaired renal function is also advised in official documents.

Q: How quickly does Keflor usually start working after the first dose?

Official pharmacokinetic studies indicate that Keflor reaches its maximum concentration in the blood, known as peak plasma concentration, between 0.5 and 1 hour after an oral dose. While the drug is rapidly absorbed, the onset of clinical improvement in infection symptoms is not necessarily simultaneous with peak absorption.

Q: Why is it important to finish the entire course of Keflor even if symptoms improve?

Official patient instructions emphasize the importance of completing the full course of treatment as prescribed. Regulatory guidance states that stopping the medication early, even if symptoms have improved, may allow some bacteria to survive and the infection could return, potentially making it harder to treat.

Q: Is it safe to consume alcohol in moderation while on Keflor?

According to official sources, Cefaclor does not have a direct chemical interaction with alcohol. While no direct interaction is noted, since Keflor is documented to cause nausea, official guidance notes that alcohol consumption could potentially worsen these gastrointestinal effects.

Q: What should a patient do if they miss a dose of Keflor?

Official guidance describes the recommended action for a missed dose as taking it when remembered, unless it is nearly time for the next dose, in which case the missed dose is omitted. Regulatory guidance explicitly advises against taking double or extra doses to compensate for a forgotten one.

Q: Is Keflor a habit-forming drug or does it have addictive properties?

Keflor (Cefaclor) is consistently classified as non-habit-forming in regulatory drug information databases. This means the medicine is not associated with addictive properties.

Q: Can Keflor cause thrush (fungal/yeast infections) in the mouth or genital area?

Official patient information acknowledges that Keflor can cause opportunistic fungal infections. This may include oral thrush (described as a white, furry sore tongue) and vaginal thrush (sore and itchy vagina with discharge).

Q: Are there any known interactions between Keflor and common over-the-counter pain relievers?

Official information indicates that certain common pain relievers, such as Paracetamol (acetaminophen), have been noted to interact with Cefaclor. However, the clinically noted significance of this interaction is generally described as minor or moderate.

Q: Is Keflor used for prophylaxis (preventing infection) in certain situations?

While Keflor is primarily used for treating active infections, it has been examined for use in certain prevention scenarios (prophylaxis). It has been studied as an alternative agent for preventing recurrent urinary tract infections (UTI).

Q: Does Keflor treatment typically require regular blood work or monitoring?

Regulatory documents recommend close monitoring and appropriate laboratory tests for patients with markedly impaired kidney function. Furthermore, official information describes that regular monitoring of prothrombin time is recommended for patients taking oral anticoagulants concomitantly.

Q: How long after finishing Keflor can side effects like diarrhea persist?

Official patient information describes that severe symptoms, such as abdominal cramps or watery diarrhea, have been reported to occur several weeks after finishing the course of antibiotic treatment.

Q: Is Keflor associated with any symptoms like confusion or hallucinations?

The official drug label reports that confusion and hallucinations are listed as rare adverse reactions affecting the nervous system. These symptoms are documented under the adverse reactions section, though they are not among the most common effects.

Q: What is the information on using Keflor if a patient also has a history of liver disease?

Official safety advice suggests Keflor should be used with caution in patients with a known history of liver disease. This advice is provided due to limited clinical data on the drug's use in severe cases of hepatic impairment.

Q: Can Keflor cause changes in personality or mood swings?

Official patient information reports that personality changes are listed as an adverse effect associated with more severe nervous system reactions like confusion and seizures. Other documented nervous system adverse effects include hyperactivity and nervousness.

Storage and Disposal of Cefaclor (Keflor): Official Regulatory Requirements

The required storage conditions for cefaclor depend on the form of the medication.

---

Storage Conditions

Form	Temperature Requirement	Stability / Container Rules
Capsules, Tablets, Dry Powder	Store at Controlled Room Temperature (15 C to 30 C).	Must be kept in a tight, light-resistant container.
Reconstituted Suspension	Must be stored in a refrigerator.	Stable for 14 days; discard any unused portion after this time.

---

Protection and Disposal

All forms must be stored out of reach of children.

For disposal, unused or expired cefaclor should not be flushed. Regulatory guidelines recommend using an official drug take-back program. If unavailable, the medication should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and placed in a sealed bag before being disposed of in the household trash.